Maccura Biotechnology Co.Ltd(300463) 4 on the evening of April 19, the annual report of 2021 was released. The company achieved an operating revenue of 3.981 billion yuan in 2021, with a year-on-year increase of 7.47%; The net profit attributable to the shareholders of the listed company was 957 million yuan, a year-on-year increase of 20.49%; The basic earnings per share is 1.73 yuan. The company plans to distribute a cash dividend of 4.68 yuan (including tax) to all shareholders for every 10 shares.
In 2021, the sales revenue of the company’s independent products was 2.3 billion yuan, a year-on-year increase of 24.08%. The annual report shows that the company’s independent products cover platforms such as biochemistry, immunity, temporary inspection, molecule, rapid inspection, pathology and raw materials. Under the orderly deployment of medium and long-term product planning, each product platform continues to push through the old and bring forth the new, which has become the source power of the company’s long-term sustainable development and an important factor driving the company’s performance. The continuous enrichment of independent products can not only improve the market share of each segment, but also work well with each product line to enhance the core competitiveness of the enterprise and increase the overall business performance of the company. During the reporting period, 42 new products were added and 463 product registration certificates were obtained. In addition, with the continuous improvement of the ability of independent products, adjusting the business structure has become an important goal of the company. In recent years, the company’s independent products have maintained rapid growth and their proportion in sales revenue has increased rapidly, and the cost advantage of independent products is much higher than that of agent products. Therefore, the adjustment of independent product structure drives the growth of the company’s performance. During the reporting period, the proportion of sales of independent products has increased from 50.03% to 57.77%, while the gross profit margin of independent products in 2021 is 79.09%, The gross profit margin of agent products in 2021 is 27.26%. Therefore, the gross profit margin of Mike’s product driven comprehensive sales increased to 58% from 53% in the same period last year, and 86% of the company’s net profit came from independent products.
Maccura Biotechnology Co.Ltd(300463) revealed that the company has established and implemented the industrial layout of the whole product line. At this stage, the company has ushered in a period of rapid development of independent products. In 2022, the company will concentrate advantageous resources, strengthen integrated innovation and accelerate the realization of phased objectives of products on various platforms. It not only realizes the continuous iteration of high-quality projects and technologies on the traditional product platform to become a first-class brand in China, but also realizes the orderly promotion and breakthrough in the new technology platform to produce high-value products. All product platforms cooperate to ensure the steady realization of industrial layout and become an integrated supplier of the global diagnostic industry. At the same time, facing the development trend of the industry, the company takes the market as the guidance and puts forward the strategic goal of developing the whole product line to systematization, serialization, automation and autonomy.
